This document provides an overview of Kangjia Cai Products and its business model, leadership, history, products, competition and predictions for the drug Favipiravir. It notes that Kangjia Cai Products has diversified over time from photographic film to materials technology and digital document systems. The company's leadership includes Shigehiro Nakajima, Shigetaka Komori and Kenji Sukeno. Favipiravir was originally developed to treat influenza and is now being studied as a potential treatment for COVID-19.